Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC05F01 in Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
NCT06873555Phase 2Recruiting
- Sponsor
- HeraNova Lifesciences
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DC05F01 in ovarian cancer, small cell lung cancer (SCLC) and solid tumor (4 arms), sponsored by HeraNova Lifesciences. Primary endpoints: Overall Response Rate at 24 months and Progression-Free Survival at 24 months. Started Sep 2024; status: recruiting.
02
Drugs
DC05F01
03
Conditions
ovarian cancersmall cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT06873555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873555.